GlassScriptPhysician profile
Ian Scott Gilson
NPI 1225028855
$9,070.20
in general payments reported to CMS, 2019-2025
41 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $1,180 · 2021: $1,311 · 2022: $1,151 · 2023: $541 · 2024: $931 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $944.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $866.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $861.10 | 2019-2025 | Ofev, Jardiance, Combivent Respimat |
| Lilly USA, LLC | $819.18 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $783.89 | 2019-2025 | |
| Abbvie INC. | $665.43 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $613.31 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Amgen INC. | $467.69 | 2019-2024 | Repatha, Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $355.01 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $324.70 | 2021-2025 | |
| Amarin Pharma, INC. | $276.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.89 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $205.09 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $200.21 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.20 | 2025 | Caplyta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Gilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.